Established in 1999, Prolacta Bioscience is a privately held life sciences company that has touched the lives of more than 90,000 premature infants globally.1
Available in hospitals since 2006, our 100% human milk-based fortifiers changed the standard of care for extremely premature infants worldwide. These are the first nutritional fortifiers made from 100% donor human milk instead of cow milk.
For financial results, disclosures and other investor information, reach out to:
David Steinberg, CFO
Our line of human milk-based fortifiers is currently on the market in 9 countries. Most recently, our fortifier for infants recovering from cardiovascular surgeries became available in Germany and Austria. We are also continuing our efforts to bring our products to more patients throughout Europe and the rest of the world.
In addition to exploring innovations and product line extensions for our core nutrition business, we are actively considering business development opportunities. Further, our promising orphan drug pipeline is focused on finding new innovative therapies for indications with highly unmet needs such as Allo-HCT, solid organ transplantation, among others.
Novel research illuminates breast milk’s unique contribution to COVID-19 defense in infants
Real-world data on human milk-based fortification reveals limitations of protocol designs of two RCTs
Prolacta's human milk-based nutrition has touched the lives of 100,000 Premature and Critically Ill Infants Globally
Prolacta Bioscience recognizes advances in preterm care during NICU awareness month
Prolacta Bioscience applauds Ohio legislature for supporting Medicaid reimbursement for donor human milk-derived products
New study shows Prolacta’s human milk-based nutritional fortifiers save hospital NICUs up to $3.4M annually
Study reveals Prolacta’s 100% human milk-based nutritional fortifiers significantly increase bioactive proteins and antioxidant activity in human milk samples, outperforming cow milk-based fortifier
Prolacta Bioscience celebrates donor moms on World Human Milk Donation Day
Prolacta Bioscience recognizes contributions of breast milk donors during National Nutrition Month
The Prolacta Bioscience Foundation empowers parents and communities with over half a million dollars in grant funding in 2022
Hot Topics in Neonatology 2022 Conference will include symposium on benefits of vat pasteurization for human donor milk
Prolacta Clinical Advisory Board members present webinar on improved growth metrics for preterm infants fed an exclusive human milk diet
Prolacta Bioscience recognizes nurses caring for fragile infants every day throughout Neonatal Nurses Week and NICU Awareness Month
Prolacta Bioscience celebrates Prematurity Awareness Month and World Prematurity Day by recognizing the contributions of breast milk donors, parents of premature infants, and the NICU teams who care for them
New study finds improved long-term neurodevelopmental outcomes for extremely premature infants fed Prolacta’s exclusive human milk diet (EHMD)
Breaking data on the efficacy and cost-effectiveness of an exclusive human milk diet for premature infants to be presented at the American Academy of Pediatrics 2022 National Conference
New peer-reviewed study finds vat pasteurization retains molecular structure of naturally occurring bioactive proteins in human donor milk, similar to raw breast milk
Prolacta Bioscience celebrated Breastfeeding Awareness Month by recognizing the commitment of NICU parents to their infants’ health
Prolacta Bioscience Appoints Dr. Erin Hamilton Spence as Director of Clinical Education and Professional Development
Multiple peer-reviewed studies show Prolacta’s 100% human milk-based nutritional fortifiers reduce risk of life-threatening comorbidities in premature infants, compared to cow milk-based nutrition
Prolacta Bioscience introduces its first evidence-based feeding protocol for an exclusive human milk diet in the NICU
Prolacta Bioscience appoints David Steinberg as chief financial officer
International Conference on Human Milk Science & Innovation to discuss latest research on bioactivity and neurodevelopment
Alecia-Jane Twigger, Ph.D., wins the Ruth A. Lawrence Investigator Award for outstanding contributions to advancing human milk science
Independent, head-to-head study shows significant health benefits of early fortification associated with Prolacta Bioscience’s 100% human milk-based fortifiers compared to cow milk-based fortifiers for premature infants
Should human milk-based nutritional products for premature infants be homogenized? More research is needed, new journal article says
Prolacta Bioscience enrolls first infant in Japan-based clinical trial to evaluate the effect of an Exclusive Human Milk Diet on growth and safety in premature infants
Prolacta Bioscience Appoints Dr. Anne Beal to Board of Directors
Prolacta Bioscience Celebrates Prematurity Awareness Month by Recognizing Breast Milk Donors for Their Contributions to Premature Infants in the NICU
Prolacta Bioscience Develops World’s First Test to Directly Detect Bacteria and Viruses, Including SARS-CoV-2, in Donor Breast Milk
Mindy Fuzesy presents at Association of Women's Health, Obstetric and Neonatal Nurses 2021 virtual convention
Prolacta Bioscience continues Advancing the Science of Human Milk, proud to partner with NICU teams in saving lives of premature infants
Association of Women’s Health, Obstetric, & Neonatal Nurses (AWHONN) encourages an exclusive human milk diet (EHMD) for vulnerable preterm infants in the neonatal intensive care unit (NICU)
Prolacta Bioscience hosts panel session on the need for uniform human milk safety standards at 2021 National Coalition for Infant Health Summit
Prolacta Bioscience supports Breastfeeding Awareness Month with donation of breast pumps to Alliance for Black NICU Families
Prolacta Bioscience congratulates Carolyn TenEyck, RN, on lifetime achievement award from National Black Nurses Association
Enrollment completed in clinical trial evaluating effect of exclusive human milk diet including a specialty fortifier in term infants born with single ventricle physiology
Four studies showed Prolacta Bioscience’s 100% human milk-based fortifiers reduced retinopathy of prematurity (ROP) in premature infants
Prolacta Bioscience provides update on latest SARS-CoV-2 data and continued safety of its human milk-based nutritional products
Late-onset sepsis reduced in premature infants fed Prolacta’s 100% human milk-based fortifiers as part of an exclusive human milk diet
Research suggests some premature infants may go home from the NICU Up to 3 weeks earlier when fed Prolacta’s 100% human milk-based nutritional products; those with bronchopulmonary dysplasia may benefit the most
Prolacta Bioscience fortifiers reduce risk of serious lung disease and hospital costs among premature infants, compared to cow milk-based fortifiers
Multiple NICUs showed improved growth & lung health in premature infants by fortifying feeds safely in the first days of life with Prolacta’s 100% human milk-based fortifiers
The preemie parent’s survival guide to the NICU now reflects the latest clinical advancements to better support parents worldwide
